Navigation Links
Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
Date:12/19/2007

FDA Offers Special Protocol Assessment for Reviroc

AMSTERDAM, December 19 /PRNewswire/ -- Kiadis Pharma announced today that it has successfully completed an End of Phase II meeting for Reviroc with the U.S. Food and Drug Administration (FDA). Reviroc is under development for elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients. The FDA agreed that the data from the completed phase II clinical Reviroc trial is sufficient to support the start of a phase III study. The FDA offered Kiadis Pharma its Special Protocol Assessment (SPA) procedure allowing Kiadis Pharma to work directly with the FDA to optimize the clinical design of the trial.

The FDA meeting followed the successful completion of a multi centre phase II study for Reviroc showing an improved overall survival after autologous bone marrow transplantation in Non-Hodgkin's lymphoma patients. The phase III clinical trial design for Reviroc will focus on patients with Large B cell lymphoma. Kiadis Pharma anticipates filing of the IND, SPA request and Orphan Drug Designation application with the FDA within the next few weeks.

"We are very pleased with the outcome of the End of Phase II meeting with the FDA and with the possibility to access the FDA's Special Protocol Assessment program. Together with the strong support by our principal investigators we are well prepared to design a clear path towards marketing authorization for Reviroc," said Manja Bouman, CEO Kiadis Pharma.

About Reviroc

Reviroc is being developed as a treatment that eliminates blood cancer cells from autologous transplants for patients with end stage blood cancer. An autologous transplant uses the patient's own bone marrow to serve as a graft. Bone-marrow transplants are broadly recognized as a treatment option for patients suffering from blood cancers, such as leukemia and lymphoma. One of the limitations of autologous bone mar
'/>"/>

SOURCE Kiadis Pharma
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Scheduled for Thursday, May 7, 2009 at 5:30 p.m. Eastern ... ALXA ) announced today that it will release ... on Thursday, May 7, 2009, following the close of the ... conference call to discuss the financial results and other clinical ...
... at 5:00 p.m. ET (22:00 CET)NOVATO, Calif., April 30 , ... ... BioMarin Revenue $74.0 ... $71.9 ...
... Bio, Maxis IT and Rescentris recognized for their innovation across the ... ... Boston (PRWEB) April 30, 2009 -- CHI,s Bio-IT World Conference ... named Best of Show Awards winners at a ceremony held Tuesday, ...
Cached Biology Technology:Alexza to Announce 2009 First Quarter Financial Results and Update Its Clinical Pipeline Status on Thursday, May 7, 2009 2Alexza to Announce 2009 First Quarter Financial Results and Update Its Clinical Pipeline Status on Thursday, May 7, 2009 3BioMarin Announces First Quarter 2009 Financial Results 2BioMarin Announces First Quarter 2009 Financial Results 3BioMarin Announces First Quarter 2009 Financial Results 4BioMarin Announces First Quarter 2009 Financial Results 5BioMarin Announces First Quarter 2009 Financial Results 6BioMarin Announces First Quarter 2009 Financial Results 7BioMarin Announces First Quarter 2009 Financial Results 8BioMarin Announces First Quarter 2009 Financial Results 9BioMarin Announces First Quarter 2009 Financial Results 10BioMarin Announces First Quarter 2009 Financial Results 11BioMarin Announces First Quarter 2009 Financial Results 12BioMarin Announces First Quarter 2009 Financial Results 13BioMarin Announces First Quarter 2009 Financial Results 14BioMarin Announces First Quarter 2009 Financial Results 15BioMarin Announces First Quarter 2009 Financial Results 16Best of Show Awards Winners Named at Bio-IT World Conference & Expo 2Best of Show Awards Winners Named at Bio-IT World Conference & Expo 3Best of Show Awards Winners Named at Bio-IT World Conference & Expo 4Best of Show Awards Winners Named at Bio-IT World Conference & Expo 5
(Date:4/15/2014)... have found a less invasive way to extract ... study how the mouth,s natural defenses ward off ... immune cells (white blood cells known as "leukocytes") ... mouthor reject foreign tissues, such as in failed ... and preventing such health issues as oral cancers, ...
(Date:4/15/2014)... in the world for which no pharmaceutical treatment exists. ... by mosquitoes in the tropics, as well as a ... and is easily spread by the hands and can ... , Researchers at Aalto University and the University of ... prevent the spread of one type of virus into ...
(Date:4/15/2014)... April 15, 2014 New research, partially funded by ... Federation, shows that consumers can improve their diets simply ... their daily meals. , In a ... and Nutrition Sciences , lead author Theresa Nicklas, DrPH, ... and Nutrition Examination Survey datasets from 2005-2010 and evaluated ...
Breaking Biology News(10 mins):New method isolates immune cells for researchers to study how they ward off oral diseases 2Nanocrystalline cellulose modified into an efficient viral inhibitor 2Eating rice boosts diet quality, reduces body weight and improves markers for health 2Eating rice boosts diet quality, reduces body weight and improves markers for health 3
... added to the threatened species list nearly three years ago ... a warming climate. , But it appears the Arctic icons ... study published in this week,s issue of the journal ... no "tipping point" that would result in unstoppable loss of ...
... appearing in the January Journal of Lipid Research ... in any significant amount in multiple sclerosis patients, contradicting ... cholesterol metabolites were associated with MS and could be ... are somewhat controversial in science; while some laboratory experiments ...
... The virus that causes AIDS is chameleon-like in its ... mutates into forms that can evade even the best ... change as they reproduce is key to developing better ... Journal of Biological Chemistry and Nature Structural & ...
Cached Biology News:Polar bears: On thin ice? Extinction can be averted, scientists say 2Polar bears: On thin ice? Extinction can be averted, scientists say 3Link between cholesterol compound and multiple sclerosis unlikely, researchers say 2New discoveries make it harder for HIV to hide from drugs 2
Mouse polyclonal antibody raised against a partial recombinant WRB. NCBI Entrez Gene ID = 7485...
...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
Mouse monoclonal antibody raised against a partial recombinant FAAH. NCBI Entrez Gene ID = FAAH...
Biology Products: